Equity Profile

AMGN

Amgen Inc.

Health CareBiotechnology$182.3B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Amgen Inc. is a leading biotechnology company that develops and manufactures innovative therapies for serious illnesses....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of profitability and will indicate how well Amgen is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and increase sales, which is vital for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

AMGN Q2-2026 Earnings Preview

Context

Company Snapshot

Amgen Inc. is a leading biotechnology company that develops and manufactures innovative therapies for serious illnesses. Operating in the Health Care sector, Amgen focuses on areas such as oncology, cardiovascular disease, and inflammation, making it a key player in addressing major health challenges.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+10.24%

Avg Stock Reaction

-0.15%

Last Quarter Recap

In Q1-2026, Amgen reported an EPS of $5.15, exceeding expectations by 8.88%. The stock reacted positively, gaining 2.43% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of Amgen's Q2-2026 earnings report, especially given the company's strong track record of beating EPS estimates.

Bull Case

If Amgen continues its trend of exceeding EPS expectations, it could signal strong operational performance and boost investor confidence.

Bear Case

Conversely, if Amgen fails to meet expectations or shows signs of slowing growth, it could lead to a decline in stock price and investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS for Q2-2026?

Given Amgen's history of beating EPS estimates, this number will be crucial in determining market reaction and investor confidence.

How is Amgen addressing competition in the biotechnology sector?

Understanding Amgen's competitive strategy will help investors gauge its future growth potential and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

While the Street expects steady growth, Amgen's recent innovations in drug development may lead to higher-than-expected revenue growth this quarter.

Supporting Evidence

Amgen has consistently beaten EPS estimates, indicating strong operational efficiency.

The options market is pricing a larger move than historical averages, suggesting potential for significant surprises.

Key Risk

If Amgen's new product launches significantly outperform expectations, it could disrupt current revenue projections.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will either reinforce Amgen's growth trajectory or highlight potential weaknesses in its business model.

Bull Confirmed If

A reported EPS of $5.50 or higher would confirm the bull case and suggest strong operational performance.

Bear Confirmed If

An EPS below $4.80 would indicate potential challenges and confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±3.48%

Historical Avg

±1.1%

Pricing rich

The options market is pricing in a potential move of about 3.48% in either direction, suggesting uncertainty around the earnings report.

Options are pricing ±3.5% while AMGN has averaged ±1.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

24.6%

Calls (248K)P/C Ratio: 0.58Puts (419K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Amgen beats expectations, history suggests the stock could rise by around 2.43%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

Should Amgen miss expectations, the stock could decline, with historical patterns indicating a potential drop of around 2.45%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·2 sells

Members

House only

Est. Notional

$18,004.00–$95,000.00

disclosed dollar ranges

Most Active Members

R-OHDavid J. TaylorRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug approvals and their expected impact on revenue.
2Management's commentary on competitive pressures in the biotechnology space.
3Insights into research and development progress for upcoming therapies.
4Guidance on revenue expectations for the next quarter.
5Any changes in pricing strategies for existing products.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Amgen Inc. is a leading biotechnology company that develops and manufactures innovative therapies for serious illnesses....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of profitability and will indicate how well Amgen is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and increase sales, which is vital for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

AMGN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+10.24%

Avg Stock Reaction

-0.15%

Last Quarter Recap

In Q1-2026, Amgen reported an EPS of $5.15, exceeding expectations by 8.88%. The stock reacted positively, gaining 2.43% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of Amgen's Q2-2026 earnings report, especially given the company's strong track record of beating EPS estimates.

Bull Case

If Amgen continues its trend of exceeding EPS expectations, it could signal strong operational performance and boost investor confidence.

Bear Case

Conversely, if Amgen fails to meet expectations or shows signs of slowing growth, it could lead to a decline in stock price and investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS for Q2-2026?

Given Amgen's history of beating EPS estimates, this number will be crucial in determining market reaction and investor confidence.

How is Amgen addressing competition in the biotechnology sector?

Understanding Amgen's competitive strategy will help investors gauge its future growth potential and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

While the Street expects steady growth, Amgen's recent innovations in drug development may lead to higher-than-expected revenue growth this quarter.

Supporting Evidence

Amgen has consistently beaten EPS estimates, indicating strong operational efficiency.

The options market is pricing a larger move than historical averages, suggesting potential for significant surprises.

Key Risk

If Amgen's new product launches significantly outperform expectations, it could disrupt current revenue projections.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will either reinforce Amgen's growth trajectory or highlight potential weaknesses in its business model.

Bull Confirmed If

A reported EPS of $5.50 or higher would confirm the bull case and suggest strong operational performance.

Bear Confirmed If

An EPS below $4.80 would indicate potential challenges and confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±3.48%

Historical Avg

±1.1%

Pricing rich

The options market is pricing in a potential move of about 3.48% in either direction, suggesting uncertainty around the earnings report.

Options are pricing ±3.5% while AMGN has averaged ±1.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

24.6%

Calls (248K)P/C Ratio: 0.58Puts (419K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Amgen beats expectations, history suggests the stock could rise by around 2.43%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

Should Amgen miss expectations, the stock could decline, with historical patterns indicating a potential drop of around 2.45%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·2 sells

Members

House only

Est. Notional

$18,004.00–$95,000.00

disclosed dollar ranges

Most Active Members

R-OHDavid J. TaylorRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug approvals and their expected impact on revenue.
2Management's commentary on competitive pressures in the biotechnology space.
3Insights into research and development progress for upcoming therapies.
4Guidance on revenue expectations for the next quarter.
5Any changes in pricing strategies for existing products.